Nancy Lin, MD | Authors

Articles

HER2CLIMB Regimen Can Be Used Earlier in HER2+ Metastatic Breast Cancer

September 16, 2020

Nancy U. Lin, MD, discusses how she would use the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine now that it has been approved for treatment of patients with HER2-positive metastatic breast cancer.

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

July 01, 2020

Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases.